pursuant to SEBI Circular dated 10th August, 2021, we hereby confirm that for the financial year ended 31st March, 2025, Jenburkt Pharmaceuticals limited is " not a large corporate" as ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals Ltd has submitted a regulatory disclosure to BSE stating that for the financial year ended 31st March 2025, it does not qualify as a 'large corporate' under SEBI's circular dated 10th August 2021. The classification is based on criteria mentioned in Clause 2.1 of Chapter XII of the circular, which typically involves thresholds on outstanding borrowing and credit ratings. The disclosure was signed by Dilip H. Bhuta (Whole Time Director & CFO) and Ashish R. Shah (Company Secretary). This is a routine annual compliance filing with no financial impact.
This is a routine regulatory disclosure with no material impact on shareholders or stock price. It simply confirms the company falls outside the SEBI framework that mandates large corporates to raise a minimum portion of borrowings through debt securities.